Oxford Nanopore makes stellar debut on UK stock market
pharmaphorum
OCTOBER 1, 2021
The debut – raising upwards of £350 million from new shares – is the largest IPO for a UK biotech company since allergy drug specialist Circassia in 2014.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
- Strictly Necessary: Used for the proper function of the website
- Performance/Analytics: Used for monitoring website traffic and interactions
- Pharmacy
- Medicine
- Nurses
- Marketing
- Research
- Behavioural Health
- Clinical Research
- Clinical Supply
- Vaccination
52
About
Webinars
About
Editions
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy | Cookie Settings
© Aggregage 2025
Let's personalize your content